NCT03226171View on ClinicalTrials.gov

Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

June 20, 2017

Primary Completion Date

September 11, 2018

Study Completion Date

September 11, 2018

Conditions
Secondary Hyperparathyroidism
Interventions
DRUG

Dose-adjusted SK-1403

SK-1403 is to be administered to patients for the whole treatment periods (52 weeks), with individual dose adjustment

Trial Locations (1)

Unknown

Investigational site (there may be other sites in this country), Tokyo

All Listed Sponsors
lead

Sanwa Kagaku Kenkyusho Co., Ltd.

INDUSTRY

NCT03226171 - Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism | Biotech Hunter | Biotech Hunter